PressFebruary 17, 2023 Numinus Wellness Announces Voting Results From its Annual General and Special Meeting of Shareholders
PressFebruary 17, 2023 Israel-Based Clearmind Medicine Strengthening IP Portfolio with Three Provisional Patent Applications in the US
PressFebruary 17, 2023 First Subject Dosed in Small Pharma’s First-in-Human Phase I Clinical Trial with SPL028
PressFebruary 17, 2023 Seelos Therapeutics Announces Completion of Enrollment of its Phase II/III Trial of SLS-005 in Amyotrophic Lateral Sclerosis on the HEALEY ALS Platform
PressFebruary 17, 2023 Delix Therapeutics Partners With Cellectricon, Expressive Neuroscience and Expands Science Team To Accelerate Drug Discovery and Translatability
BlogFebruary 16, 2023 Cody Shandraw, Founder of Healing REIT, Sits in the Investor Hotseat on February 23rd
PressFebruary 14, 2023 Filament Health Announces Second Psilocybin Supply Agreement with the Centre for Addiction and Mental Health
PressFebruary 14, 2023 Israel-Based Clearmind Medicine to Present at The OurCrowd Global Investor Summit Sponsored by Greenberg Traurig Tel Aviv
PressFebruary 14, 2023 PharmAla Biotech Closes Purchase Order With Emyria Ltd., Completes Filing of “LaNeo” Trademark in Australia
PressFebruary 14, 2023 Reunion Neuroscience Provides Business Update and Reports Fiscal Third Quarter 2023 Financial Results
PressFebruary 10, 2023 Mydecine Innovations Group Announces Closing Under Share Subscription Agreement
PressFebruary 10, 2023 Silo Pharma Inc. Partnering to Transform Health Care, Improve Patient Outcomes
PressFebruary 10, 2023 FSD Pharma Inc. Receipt of No Objection Letter from Health Canada Is Focus of Recent InvestmentPitch Media Video
PressFebruary 10, 2023 Bright Minds Biosciences Announces Receipt of Nasdaq Deficiency Letter Regarding Independent Director and Audit Committee Requirements
PressFebruary 10, 2023 Israeli- Based Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity
BlogFebruary 9, 2023 Microdosing is Now Legal in Oregon—What Does it Mean for the Psilocybin Community?
PressFebruary 8, 2023 Optimi Health Submits Phase I Clinical Trial Application Combining The Use Of Proprietary Psilocybin and MDMA Drug Candidates In Healthy Therapists
PressFebruary 8, 2023 PharmaTher Submits FDA Meeting Package to Discuss 505(b)(2) Pathway for New Drug Application of KETARX™ (Ketamine) On-Body Pump System
PressFebruary 8, 2023 Revive Therapeutics Secures MDMA Supply from PharmAla Biotech for MDMA Transdermal Patch Development
PressFebruary 6, 2023 Lobe Sciences Congratulates Australia for Becoming the First Nation to Approve the Medicinal Use of Psilocybin and MDMA
